Michelle D. Kelsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle D. Kelsey has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Pamela S. Douglas
Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina
8 shared publications - Neha J. Pagidipati
Duke University School of Medicine
6 shared publications - Michael G. Nanna
Section of Cardiovascular Medicine, Department of Medicine Yale School of Medicine New Haven Connecticut USA
4 shared publications - Campbell Rogers
HeartFlow, Inc, Mountain View, California, USA
3 shared publications - Daniel B. Mark
Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA; Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
3 shared publications - Manesh R. Patel
Medicine, Duke University, Durham, North Carolina, USA
3 shared publications
Latest Publications
- 8 September 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (11)
From Atherosclerosis to Heart Failure
- 8 September 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (11)
From Atherosclerosis to Heart Failure
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , JC100
In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , JC100
In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y
- 4 June 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 167, 108369
Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study
- 4 June 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 167, 108369
Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (3) , e019011
Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial
BACKGROUND: Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain. METHODS: We analyzed data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) coronary computed tomography angiography arm, quantifying total coronary plaque volume and burden (plaque burden [PB]; % vessel volume), including calcified, noncalcified, and low-attenuation components. Associations with major adverse cardiovascular events (death, myocardial infarction, or unstable angina hospitalization) were assessed using sex-stratified spline Cox models over a median 26 months (interquartile range, 18–34). RESULTS: Among 4267 patients (mean age, 60.4±8.2; 2199 women), plaque was less frequent in women (55% versus 75%; P <0.001), with lower total plaque volume but similar total PB and incident major adverse cardiovascular events (2.3% versus 3.4%). Major adverse cardiovascular event risk became elevated at lower PB in women than in men: for total PB, hazard ratio crossed 1.0 at 20% in women versus 28% in men, reaching hazard ratio 1.5 at 32% in women versus 42% in men, respectively. Noncalcified PB showed a similar pattern, crossing hazard ratio 1.0 at 7% in women versus 9% in men; hazard ratio 1.5 at 13% in women versus 20% in men. Findings were similar after adjustment for atherosclerotic cardiovascular disease risk score. CONCLUSIONS: In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (3) , e019011
Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial
BACKGROUND: Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain. METHODS: We analyzed data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) coronary computed tomography angiography arm, quantifying total coronary plaque volume and burden (plaque burden [PB]; % vessel volume), including calcified, noncalcified, and low-attenuation components. Associations with major adverse cardiovascular events (death, myocardial infarction, or unstable angina hospitalization) were assessed using sex-stratified spline Cox models over a median 26 months (interquartile range, 18–34). RESULTS: Among 4267 patients (mean age, 60.4±8.2; 2199 women), plaque was less frequent in women (55% versus 75%; P <0.001), with lower total plaque volume but similar total PB and incident major adverse cardiovascular events (2.3% versus 3.4%). Major adverse cardiovascular event risk became elevated at lower PB in women than in men: for total PB, hazard ratio crossed 1.0 at 20% in women versus 28% in men, reaching hazard ratio 1.5 at 32% in women versus 42% in men, respectively. Noncalcified PB showed a similar pattern, crossing hazard ratio 1.0 at 7% in women versus 9% in men; hazard ratio 1.5 at 13% in women versus 20% in men. Findings were similar after adjustment for atherosclerotic cardiovascular disease risk score. CONCLUSIONS: In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , JC16
In patients with CAD, clopidogrel vs. aspirin monotherapy reduces MACCE without increasing major bleeding
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , JC16
In patients with CAD, clopidogrel vs. aspirin monotherapy reduces MACCE without increasing major bleeding
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
- 23 July 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (11) , 1279-1281
Sex-Specific Prognostic Value of Quantifying Coronary Plaque in Patients With Stable Chest Pain
- 23 July 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (11) , 1279-1281
Sex-Specific Prognostic Value of Quantifying Coronary Plaque in Patients With Stable Chest Pain
- 1 March 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (3) , JC32
In patients with acute MI, colchicine did not reduce cardiac events at 3 y
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
- 1 March 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (3) , JC32
In patients with acute MI, colchicine did not reduce cardiac events at 3 y
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
- 1 March 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (3) , JC33
In patients with acute MI, spironolactone did not reduce cardiac events at 3 y
Cardiology: [Formula: see text].
- 1 March 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (3) , JC33
In patients with acute MI, spironolactone did not reduce cardiac events at 3 y
Cardiology: [Formula: see text].
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e011414
Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial
BACKGROUND: The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) trial compared an investigational precision diagnostic testing strategy (n=1057) with usual testing (n=1046) in patients with stable chest pain and suspected coronary artery disease. Quality of life (QOL) outcomes were a prespecified secondary end point. METHODS: We assessed QOL by structured interviews in all trial participants at baseline and 45 days, 6 months, and 12 months postrandomization. QOL assessments included angina-related QOL (19-item Seattle Angina Questionnaire [SAQ-19]), generic health status (EQ-5D), and a 4-item care satisfaction survey (at 45 days only). The prespecified primary comparison was the 6-month SAQ Summary score outcomes (scale, 0 to 100; higher scores indicate greater health status). QOL data collection rates were high, with 99% complete baseline SAQ scores and 86.5% complete at the 6-month primary comparison follow-up. All comparisons were made as randomized. RESULTS: At baseline, mean SAQ Summary scores were 70.9 in the Precision Strategy group (n=1050) and 70.4 in the Usual Testing group (n=1042). By 6 months, mean SAQ Summary scores had improved to 89.9 in the Precision Strategy group and 89.2 in the Usual Testing group, with a mean adjusted difference of 0.8 (95% CI, −0.3 to 2.0). The SAQ component scores showed similar improvement from baseline in both groups and no statistically significant or clinically meaningful differences between the 2 groups at any follow-up time point. By 6 months, 66% of patients in both groups were chest pain-free. EQ-5D visual analog scores also improved from baseline and showed no difference between groups during follow-up. Care satisfaction scores were high and similar at 45 days. CONCLUSIONS: In stable patients with symptoms suggesting coronary artery disease, angina-related and overall QOL improved substantially over the initial 6 months independent of the testing strategy assigned. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03702244.
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e011414
Open AccessQuality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial
BACKGROUND: The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) trial compared an investigational precision diagnostic testing strategy (n=1057) with usual testing (n=1046) in patients with stable chest pain and suspected coronary artery disease. Quality of life (QOL) outcomes were a prespecified secondary end point. METHODS: We assessed QOL by structured interviews in all trial participants at baseline and 45 days, 6 months, and 12 months postrandomization. QOL assessments included angina-related QOL (19-item Seattle Angina Questionnaire [SAQ-19]), generic health status (EQ-5D), and a 4-item care satisfaction survey (at 45 days only). The prespecified primary comparison was the 6-month SAQ Summary score outcomes (scale, 0 to 100; higher scores indicate greater health status). QOL data collection rates were high, with 99% complete baseline SAQ scores and 86.5% complete at the 6-month primary comparison follow-up. All comparisons were made as randomized. RESULTS: At baseline, mean SAQ Summary scores were 70.9 in the Precision Strategy group (n=1050) and 70.4 in the Usual Testing group (n=1042). By 6 months, mean SAQ Summary scores had improved to 89.9 in the Precision Strategy group and 89.2 in the Usual Testing group, with a mean adjusted difference of 0.8 (95% CI, −0.3 to 2.0). The SAQ component scores showed similar improvement from baseline in both groups and no statistically significant or clinically meaningful differences between the 2 groups at any follow-up time point. By 6 months, 66% of patients in both groups were chest pain-free. EQ-5D visual analog scores also improved from baseline and showed no difference between groups during follow-up. Care satisfaction scores were high and similar at 45 days. CONCLUSIONS: In stable patients with symptoms suggesting coronary artery disease, angina-related and overall QOL improved substantially over the initial 6 months independent of the testing strategy assigned. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03702244.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e011008
Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial
BACKGROUND: The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) demonstrated that a precision diagnostic strategy reduced the primary composite of death, nonfatal myocardial infarction, or catheterization without obstructive coronary artery disease by 65% in patients with nonacute chest pain compared with usual testing. Medical cost was a prespecified secondary end point. METHODS: PRECISE randomized 2103 patients between December 2018 and May 2021 to usual testing or a precision strategy that used deferred testing for the lowest risk patients (20%) and coronary computed tomographic angiography with selective computed tomography–derived fractional flow reserve for the remainder. Resource use consumption data were collected from all study participants and hospital cost data from US participants (n=1125) to estimate total medical costs. The primary and secondary economic outcomes were total costs at 12 months and at 45 days, respectively, from the US health care system perspective. The mean cost differences between the 2 strategies were reported by intention-to-treat. RESULTS: At 45 days, total costs were similar between the precision strategy and usual testing (mean difference, $182 [95% CI, −$555 to $661]). By 12 months, percutaneous coronary intervention and coronary artery bypass surgery had been performed in 7.2% and 2.0% of precision strategy patients and 3.5% and 1.7% of usual testing patients, respectively. At 1 year, precision strategy costs were $5299 versus $4821 for usual testing (mean difference, $478 [95% CI, −$889 to $1437]; P =0.43). Precision care decreased mean per-patient diagnostic cost by 27% and increased mean per-patient revascularization costs by 67%. CONCLUSIONS: In the PRECISE trial, the precision strategy, a risk-based approach endorsed by current clinical practice guidelines, improved the clinical efficiency of testing and had similar costs to usual testing at 45 days and a nonsignificant $478 cost difference at 1 year. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03702244.
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e011008
Open AccessEconomic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial
BACKGROUND: The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) demonstrated that a precision diagnostic strategy reduced the primary composite of death, nonfatal myocardial infarction, or catheterization without obstructive coronary artery disease by 65% in patients with nonacute chest pain compared with usual testing. Medical cost was a prespecified secondary end point. METHODS: PRECISE randomized 2103 patients between December 2018 and May 2021 to usual testing or a precision strategy that used deferred testing for the lowest risk patients (20%) and coronary computed tomographic angiography with selective computed tomography–derived fractional flow reserve for the remainder. Resource use consumption data were collected from all study participants and hospital cost data from US participants (n=1125) to estimate total medical costs. The primary and secondary economic outcomes were total costs at 12 months and at 45 days, respectively, from the US health care system perspective. The mean cost differences between the 2 strategies were reported by intention-to-treat. RESULTS: At 45 days, total costs were similar between the precision strategy and usual testing (mean difference, $182 [95% CI, −$555 to $661]). By 12 months, percutaneous coronary intervention and coronary artery bypass surgery had been performed in 7.2% and 2.0% of precision strategy patients and 3.5% and 1.7% of usual testing patients, respectively. At 1 year, precision strategy costs were $5299 versus $4821 for usual testing (mean difference, $478 [95% CI, −$889 to $1437]; P =0.43). Precision care decreased mean per-patient diagnostic cost by 27% and increased mean per-patient revascularization costs by 67%. CONCLUSIONS: In the PRECISE trial, the precision strategy, a risk-based approach endorsed by current clinical practice guidelines, improved the clinical efficiency of testing and had similar costs to usual testing at 45 days and a nonsignificant $478 cost difference at 1 year. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03702244.